We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

128 hedge funds and large institutions have $1.04B invested in Aclaris Therapeutics in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more call options, than puts

Call options by funds: $483K | Put options by funds: $362K

22% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 37

18% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 11

8% more capital invested

Capital invested by funds: $957M → $1.04B (+$78.3M)

3.32% more ownership

Funds ownership: 95.35% → 98.67% (+3.3%)

1% more funds holding

Funds holding: 127 → 128 (+1)

33% less funds holding in top 10

Funds holding in top 10: 9 → 6 (-3)

Holders
128
Holders Change
+1
Holders Change %
+0.79%
% of All Funds
2.06%
Holding in Top 10
6
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-33.33%
% of All Funds
0.1%
New
13
Increased
45
Reduced
37
Closed
11
Calls
$483K
Puts
$362K
Net Calls
+$121K
Net Calls Change
+$116K

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$32.7M
2
BlackRock
BlackRock
New York
+$4.48M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$3.07M
4
Walleye Capital
Walleye Capital
New York
+$2.4M
5
HighTower Advisors
HighTower Advisors
Illinois
+$2.16M

Top Sellers

1
BI
BVF Inc
California
-$11.3M
2
CC
Commodore Capital
New York
-$8.53M
3
Holocene Advisors
Holocene Advisors
New York
-$6.39M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$6M
5
ACM
Aisling Capital Management
New York
-$3.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
26
Samsara BioCapital
California
$11M – – –
WP
27
Woodline Partners
California
$9.49M -$1.52M -94,488 -14%
Northern Trust
28
Northern Trust
Illinois
$8.94M +$225K +13,985 +3%
ACM
29
Aisling Capital Management
New York
$6.84M -$3.22M -200,000 -32%
JP Morgan Chase
30
JP Morgan Chase
New York
$6.74M -$407K -25,305 -6%
Walleye Capital
31
Walleye Capital
New York
$6.6M +$2.4M +149,136 +55%
SSA
32
Schonfeld Strategic Advisors
New York
$6.49M +$194K +12,078 +3%
Charles Schwab
33
Charles Schwab
California
$6.49M +$154K +9,579 +2%
Verition Fund Management
34
Verition Fund Management
Connecticut
$6.39M +$532K +33,061 +9%
IHAM
35
Integral Health Asset Management
New York
$5.83M +$483K +30,000 +9%
SCM
36
Silverarc Capital Management
Massachusetts
$5.55M -$3.08M -191,583 -35%
Goldman Sachs
37
Goldman Sachs
New York
$5.47M -$1.21M -74,949 -18%
PA
38
Perceptive Advisors
New York
$5.37M – – –
FLSM
39
Frazier Life Sciences Management
California
$4.57M -$1.9M -118,140 -29%
ACP
40
Acuta Capital Partners
California
$4.02M +$1.51M +94,165 +59%
PHP
41
Parkman Healthcare Partners
Connecticut
$3.89M +$218K +13,533 +6%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$3.65M -$36.5K -2,269 -1%
Millennium Management
43
Millennium Management
New York
$3.27M +$64.2K +3,993 +2%
N
44
Nuveen
North Carolina
$3.17M -$319K -19,827 -9%
Assenagon Asset Management
45
Assenagon Asset Management
Luxembourg
$3.07M – – –
HighTower Advisors
46
HighTower Advisors
Illinois
$3.03M +$2.16M +134,071 +230%
HS
47
HighVista Strategies
Massachusetts
$2.95M -$486K -30,199 -14%
Morgan Stanley
48
Morgan Stanley
New York
$2.21M -$441K -27,408 -16%
Swiss National Bank
49
Swiss National Bank
Switzerland
$1.77M +$33.8K +2,100 +2%
VOYA Investment Management
50
VOYA Investment Management
Georgia
$1.68M – – –
1
2
3 4 5

ACRS Hedge Fund Activity: Q4 2022 in Review

128 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2022, worth a combined $1.04B — up 8.2% from $957M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new ACRS positions and 11 closed out — a net gain of 2 holders — while 45 added to existing stakes and 37 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $32.7M. The largest seller was BVF Inc, cutting an estimated $11.3M.

  • 128 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2022, up from 127 in Q3 2022.
  • Funds reported $1.04B of Aclaris Therapeutics stock for Q4 2022, up 8.2% quarter-over-quarter.
  • 13 funds opened new Aclaris Therapeutics positions in Q4 2022 and 11 closed out, a net change of +2 holders.
  • The largest Aclaris Therapeutics buyer in Q4 2022 was Wellington Management Group, an estimated $32.7M added.
  • The largest Aclaris Therapeutics seller in Q4 2022 was BVF Inc, an estimated $11.3M sold.

Based on aggregated 13F filings for Q4 2022.